<DOC>
	<DOCNO>NCT00316888</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Drugs use chemotherapy , cisplatin fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Cetuximab may help cisplatin fluorouracil work well make tumor cell sensitive drug . It may also make tumor cell sensitive radiation therapy . Giving cetuximab together chemotherapy radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together cisplatin , fluorouracil , radiation therapy work treat immunocompetent patient stage I ( close accrual 11/3/2008 ) , stage II , ( stage II close accrual 11/3/2008 ) stage III anal cancer .</brief_summary>
	<brief_title>Cetuximab , Cisplatin , Fluorouracil , Radiation Therapy Treating Patients With Anal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary Objective : - Determine whether addition cetuximab combine modality therapy ( CMT ) comprise cisplatin , fluorouracil , radiotherapy reduces local failure rate ≥ 50 % 3 year ( compare historical data ) immunocompetent patient stage I-III invasive anal carcinoma . Secondary Objectives : - Determine objective response rate ( complete partial ) , progression-free survival , colostomy-free survival , overall survival . - Determine overall toxicity concurrent cisplatin , fluorouracil , radiation therapy combine cetuximab . Exploratory Objectives : - Evaluate effect cetuximab CMT anogenital herpes papilloma virus ( HPV ) infection anal cytology . - Evaluate whether moderate strong expression epidermal growth factor receptor , Phosphatidylinositol-4,5-bisphosphate 3-kinase ( PI3K ) , P-Akt ( determined immunohistochemistry ) associate increase risk local failure . OUTLINE : This multicenter study two sequential arm . Arm I close accrual 11/3/2008 , arm II open accrual 8/18/2009 . Patients assign 1 2 treatment arm . - Arm I ( close accrual 11/3/2008 ) : Patients receive cisplatin intravenously ( IV ) 60 minute day 1 , 29 , 57 , 85 fluorouracil IV continuously 96 hour day 1-4 , 29-32 , 57-60 , 85-88 . Patients also receive cetuximab IV 120 minute day 50 IV 60 minute day 57 , 64 , 71 , 78 , 85 , 92 , 99 undergo radiotherapy daily 5 day week 5 week , begin day 57 . - Arm II ( open accrual 8/18/2009 ) : Patients receive cetuximab IV 120 minute day 1 IV 60 minute day 8 , 15 , 22 , 29 , 36 , 43 , 50 . Patients also receive cisplatin IV 60 minute day 8 36 , fluorouracil IV continuously 96 hour day 8-11 36-39 , undergo radiotherapy daily 5 day week 5 week begin day 8 . After completion study treatment , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 62 patient accrue study .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>INCLUSION CRITERIA : Histologically confirm anal canal perianal ( anal margin ) squamous cell carcinoma Stage IIIIB ( close accrual 11/3/2008 ) Stage II ( T3 , N0 ) , IIIA , IIIB Tumors nonkeratinizing histology , basaloid , transitional cell , cloacogenic histology , allow No welldifferentiated stage I anal margin cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Hemoglobin ≥ 10 g/dL Platelet count ≥ 100,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) OR creatinine clearance &gt; 60 mL/min Bilirubin ≤ 2 time ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 time ULN Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No malignancy except nonmelanomatous skin cancer Prior malignancy must remission ≥ 5 year Patients know risk factor human immunodeficiency virus ( HIV ) infection must undergo HIV test within 90 day study entry AND must HIV negative antibody detection , culture , quantitative assay plasma HIV ribonucleic acid ( RNA ) EXCLUSION CRITERIA : Presence follow condition within past 6 month : Active infection Uncontrolled diabetes New York Heart Association class IIIV congestive heart failure Cerebrovascular accident Transient ischemic attack Uncontrolled hypertension Unstable angina Myocardial infarction History rheumatic disorder , irritable bowel syndrome , inflammatory bowel disease Known HIV positivity Known risk factor HIV infection Prior radiotherapy chemotherapy malignancy Prior pelvic radiotherapy Prior potentially curative surgery ( i.e. , abdominal peritoneal resection ) anal cancer Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>squamous cell carcinoma anus</keyword>
	<keyword>stage I anal cancer</keyword>
	<keyword>stage II anal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>basaloid carcinoma anus</keyword>
	<keyword>cloacogenic carcinoma anus</keyword>
</DOC>